Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 6/20 | 0.74 |
| ▸ | TGFBR2 | P37173 | 6/20 | 0.71 |
| ▸ | THRB | P10828 | 7/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818169 | 0.85 | TGFBR1 (1.00) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL411721 | 0.85 | TGFBR1 (0.75) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL412490 | 0.84 | TGFBR1 (1.00) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL373492 | 0.83 | TGFBR1 (1.00) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL413111 | 0.82 | TGFBR1 (1.00) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL414544 | 0.82 | TGFBR1 (1.00) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL4823846 | 0.81 | TGFBR1 (0.69) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL408963 | 0.80 | TGFBR1 (0.69) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL4823880 | 0.80 | TGFBR1 (0.68) | TGFBR1MAP3K20TGFBR2THRBMAPK14 | |
| SCHEMBL4815692 | 0.80 | TGFBR1 (0.68) | TGFBR1MAP3K20TGFBR2THRBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | claimed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | TGFBR1 3/4885MAP3K20 105/4885TGFBR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.